Warning letter
Gilead Sciences Inc [ARCHIVED]: warning letter of Sep 21, 2010
FDA warning letter 105726 · Los Angeles District Office
Key facts
| Reference number | 105726 |
|---|---|
| Company | Gilead Sciences Inc [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Sep 21, 2010 |
| Posted date | Sep 21, 2010 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.42(c)(10), 211.67(a), 211.100(a), 211.113(b) |
| Inspection city | San Dimas |
| Inspection ZIP | 91773 |
| Inspection start date | Jan 25, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: